UCalgary researchers collaborate with international firm to commercialize new nanomedicine

May 24, 2019

Genentech, an international biotechnology firm, has partnered with researchers out of the University of Calgary to commercialize a nanomedicine designed to protect against autoimmune diseases. “We’re thrilled that this potentially transformative and highly innovative approach, discovered through research at the University of Calgary, is advancing toward the clinic where it could possibly have the opportunity to broadly impact those who suffer from these serious diseases here in our community and around the world,” said UCalgary President Ed McCauley. “Across our campuses, our researchers are making important discoveries like this in the life sciences.” A UCalgary release states that the partners will develop treatments for celiac disease, autoimmune liver diseases, and inflammatory bowel disease. UCalgary (AB)